ArticleTrials2025
Early implantation of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with liver cirrhosis and ascites (eTIPS): a multicentre, randomised controlled trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06576934 (Early Implantation of a Transjugular Intrahepatic Portosystemic Shunt), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Implantation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients With Liver Cirrhosis and Ascites: a Multicentre, Randomised Controlled Trial
Who cites it
2 citing papers in PubMed.
- Reply to: "External validation of a simple risk stratification for portal hypertension-related clinical deterioration in patients with ascites".JHEP reports : innovation in hepatology · 2026Article
- KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications 2026.Clinical and molecular hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPortal hypertension is a major complication in patients with liver cirrhosis, leading to severe outcomes such as variceal bleeding and ascites. Transjugular intrahepatic portosystemic shunt (TIPS) has emerged as an effective interventional treatment of recurrent ascites and variceal bleeding. However, up to 30% of patients with recurrent ascites show TIPS refractory ascites, and prior data have shown that the frequency of paracenteses before TIPS implantation predicts ascites clearance indicating that TIPS implantation may be too late in some patients. Especially, patients with grade 2 ascites and a MELD score ≥ 15, or grade 3 ascites irrespective of MELD score at first decompensation with ascites face a high risk of further decompensation and mortality. Therefore, these patients may benefit from early TIPS implantation in order to improve post-TIPS mortality. We hypothesise that early TIPS implantation in these selected patients at the time of the first decompensation may improve transplantation-free survival compared to standard medical treatment (SMT).
methodsThe eTIPS study is a prospective, randomised, open, multicenter interventional, superiority trial. Patients will be randomised 1:1 in the intervention group with TIPS implantation and in the SMT group. The primary endpoint is transplantation-free survival. Secondary endpoints include the time to ascites with need for paracentesis and quality of life assessed six and 12 months after randomisation. DISCUSSION: Expanding the concept of early TIPS implantation to ascites management may offer significant survival benefits and may significantly change the treatment algorithm of patients with ascites.
trial registrationGerman Registry for Clinical Studies DRKS00034545. Registered on 20/02/2025. Clinical trials NCT06576934. Registered on 04/12/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.